A little-known cannabinoid called CBDV has been getting some serious attention lately. It has similar effects to CBD and can help support mood, healthy cellular function, normal inflammation, and control nausea.
Research shows it may also aid neurobehavioral symptoms related to autism spectrum disorder (ASD). In a 2018 rodent study, CBDV showed promise for helping the neurological and social issues associated with Rett syndrome caused by an X chromosome mutation.
Anti-Inflammatory
What is CBDV and its effects? CBDV may help alleviate inflammation by targeting neuroreceptors that control pain perception and temperature sensing. Its anti-inflammatory properties are also potentially helpful in treating digestive disorders such as ulcerative colitis.
CBD appears to bind with the same family of neuroreceptors as TRP channels, which mediate sensations inside cells. This suggests that it could treat conditions such as neuropathic pain, migraines, and seizures.
Research into CBDV has begun to gain momentum, attracting interest from pharmaceutical companies. GW Pharmaceuticals is developing a CBDV-based drug called GW42006 that is being tested to reduce or prevent seizures.
Anti-Nausea
CBDV works as a CB1 receptor inverse agonist to produce anti-nausea effects. It’s also being researched for its potential to support symptoms of autism spectrum disorder (ASD).
Preclinical studies have shown that CBDV can decrease repetitive behaviors, irritability, and cognitive and social difficulties. It has also been shown to reduce motor impairments in mice with Rett syndrome.
CBDV can help balance the activity of nerve cells responsible for inflammation, seizures, pain, and nausea. It’s currently being developed into a pharmaceutical drug to treat epilepsy by GW Pharmaceuticals. It’s also being investigated for its benefits in Duchenne muscular dystrophy (DMD), a genetic condition that causes progressive and irreversible muscle degeneration.
Anti-Seizure
CBDV has been shown to help treat childhood intractable epilepsy. It works by inhibiting the activity of a specific receptor called TRPV1, which usually sends out too many signals. CBDV can calm these channels, thereby reducing the likelihood of a seizure.
According to preclinical studies involving animal models, CBDV also effectively prevents multiple types of seizures. In one study, CBDV helped reduce the severity of seizures linked to Rett syndrome, a genetic condition.
Moreover, CBDV may help ease neuropathic pain symptoms by binding to the TRPA1 receptor. CBDV can also modulate nausea responses by acting as an agonist at CB1 receptors.
Anti-Anxiety
CBDV is a non-psychoactive cannabinoid, making it a valuable supplement for those with anxiety or who are sensitive to THC. It can also reduce nausea.
CBD has been shown to help with several conditions, including intractable childhood epilepsy and ASD. It is thought to work by binding to TRP channels, which regulate body temperature and help mediate sensations throughout the body.
Studies are underway to explore the effectiveness of CBDV in helping with some significant ASD issues, including repetitive behavior problems, cognitive challenges, and communication and social functioning. It is also being tested for its ability to treat Duchenne muscular dystrophy, a progressive degenerative muscle disease that affects boys.
Anti-Muscle Spasms
Studies indicate CBD may have therapeutic benefits for fibromyalgia, migraines, and other types of chronic pain. This rare cannabinoid may also have anti-seizure and anti-inflammatory properties.
One of the unique attributes of CBD is its ability to prevent the creation of 2-arachidonoylglycerol (2-AG), one of our body’s naturally occurring endocannabinoids. This explains why CBDV has been shown to have anti-epileptic solid properties.
In a 2018 rodent study, CBDV suppressed seizures in a genetic model of epilepsy without the uncontrollable shaking that can occur with some anti-seizure medications. Additionally, CBDV prevented memory defects in the same model. Further, CBDV reduced muscle spasticity and improved locomotion in a mouse version of Duchenne muscular dystrophy (DMD).
Anti-Degenerative
CBDV is helpful with several degenerative health issues. A study on a mouse model of Duchenne muscular dystrophy (DMD) found that CBDV improved locomotion and decreased inflammation.
The non-psychoactive cannabis molecule CBDV has attracted interest from mainstream pharmaceutical companies. GW Pharmaceuticals, the company behind the first FDA-approved CBD drug for seizures (Epidiolex), is actively exploring CBDV’s potential as an anticonvulsant.
CBDV also showed promise in aiding the neurobehavioral issues associated with an autism spectrum disorder in a rodent study. In particular, CBDV was able to help with repetitive behavior problems and communication and social impairments in the animal. It also inhibited chemically-induced seizures in rodents.
